Latigo reports Q2 2026 results, NEJM publication for onzotrigine, and completed IPO
Latigo said its Phase 3 program for onzotrigine will start in the second half of 2026, with cash it says funds operations into 2029.
SEC filing
Latest
3 stories
Thursday, September 3
Friday, August 7
Latigo Biotherapeutics prices IPO at $18 per share on Nasdaq
The clinical-stage pain drug developer sold 19.2 million shares to raise about $315.7 million in net proceeds ahead of an August 10, 2026 closing.
SEC filing
Friday, July 17
Latigo Biotherapeutics files for IPO on Nasdaq under ticker LTGO
The clinical-stage pain biotech disclosed positive Phase 3-track abdominoplasty data for lead candidate LTG-001 and plans Phase 3 bunionectomy and safety trials in the second half of 2026.
SEC filing